Literature DB >> 11580279

Constitutive activation of the mu opioid receptor by mutation of D3.49(164), but not D3.32(147): D3.49(164) is critical for stabilization of the inactive form of the receptor and for its expression.

J Li1, P Huang, C Chen, J K de Riel, H Weinstein, L Y Liu-Chen.   

Abstract

The roles of conserved aspartates in the third transmembrane domain of the rat mu opioid receptor (RMOR) were explored with mutations of D3.32(147) and D3.49(164). D3.49(164) in the highly conserved DRY motif was mutated to 13 amino acids. Except for the D3.49(164)E mutant, each mutant displayed little or no detectable [(3)H]diprenorphine binding, and pretreatment with naloxone greatly enhanced binding. D3.49(164)H, -Q, -Y, -M, and -E mutants were further studied. D3.32(147) was substituted with A or N. All seven mutants exhibited similar binding affinities for the antagonist [(3)H]diprenorphine as the wild-type. The D3.49(164)H, -Q, -Y, and -M mutants, but not the D3.49(164)E and D3.32(147) mutants, exhibited enhanced basal [(35)S]GTPgammaS binding which was comparable to the maximally activated level of the wild-type and was related to expression levels. Naloxone, naltrexone, and naloxone methiodide significantly inhibited the basal [(35)S]GTPgammaS binding of the D3.49(164) mutants, indicating inverse agonist activities. Treatment of the D3.49(164)Y mutant with pertussis toxin greatly reduced the basal [(35)S]GTPgammaS binding, demonstrating constitutive activation of Galpha(i)/Galpha(o). The D3.49(164)H, -Y, -M, and -Q mutants had higher affinities for DAMGO than the wild-type, which were not significantly lowered by GTPgammaS. Thus, mutation of D3.49(164) to H, Y, M, or Q in RMOR resulted in receptor assuming activated conformations. In contrast, the D3.49(164)E mutant displayed significantly lower basal [(35)S]GTPgammaS binding and reduced affinity for DAMGO. Upon incubation of membranes at 37 degrees C, the constitutively active D3.49(164)Y mutant was structurally less stable, whereas the inactivated D3.49(164)E mutant was more stable, than the wild-type. Computational simulations showed that the E3.49 side chain interacted strongly with the conserved R3.50 in the DRY motif and stabilized the inactive form of the receptor. Taken together, these results indicate that D3.49 plays an important role in constraining the receptor in inactive conformations.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11580279     DOI: 10.1021/bi0100945

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  18 in total

1.  Selectivity in the Use of Gi/o Proteins Is Determined by the DRF Motif in CXCR6 and Is Cell-Type Specific.

Authors:  Satya P Singh; John F Foley; Hongwei H Zhang; Darrell E Hurt; Jennifer L Richards; Craig S Smith; Fang Liao; Joshua M Farber
Journal:  Mol Pharmacol       Date:  2015-08-27       Impact factor: 4.436

Review 2.  Homology modeling of opioid receptor-ligand complexes using experimental constraints.

Authors:  Irina D Pogozheva; Magdalena J Przydzial; Henry I Mosberg
Journal:  AAPS J       Date:  2005-10-05       Impact factor: 4.009

3.  Simplified modeling approach suggests structural mechanisms for constitutive activation of the C5a receptor.

Authors:  Gregory V Nikiforovich; Garland R Marshall; Thomas J Baranski
Journal:  Proteins       Date:  2010-11-30

4.  Post-activation-mediated changes in opioid receptors detected by N-terminal antibodies.

Authors:  Achla Gupta; Raphael Rozenfeld; Ivone Gomes; Kirsten M Raehal; Fabien M Décaillot; Laura M Bohn; Lakshmi A Devi
Journal:  J Biol Chem       Date:  2008-02-06       Impact factor: 5.157

Review 5.  Mu opioids and their receptors: evolution of a concept.

Authors:  Gavril W Pasternak; Ying-Xian Pan
Journal:  Pharmacol Rev       Date:  2013-09-27       Impact factor: 25.468

Review 6.  Insights into the function of opioid receptors from molecular dynamics simulations of available crystal structures.

Authors:  Kristen A Marino; Yi Shang; Marta Filizola
Journal:  Br J Pharmacol       Date:  2017-04-12       Impact factor: 8.739

Review 7.  Cellular signalling of non-synonymous single-nucleotide polymorphisms of the human μ-opioid receptor (OPRM1).

Authors:  Alisa Knapman; Mark Connor
Journal:  Br J Pharmacol       Date:  2014-07-01       Impact factor: 8.739

8.  Phosphorylation of the mu-opioid receptor at tyrosine 166 (Tyr3.51) in the DRY motif reduces agonist efficacy.

Authors:  Cecilea C Clayton; Michael R Bruchas; Michael L Lee; Charles Chavkin
Journal:  Mol Pharmacol       Date:  2009-12-03       Impact factor: 4.436

Review 9.  The crystallographic model of rhodopsin and its use in studies of other G protein-coupled receptors.

Authors:  Slawomir Filipek; David C Teller; Krzysztof Palczewski; Ronald Stenkamp
Journal:  Annu Rev Biophys Biomol Struct       Date:  2003-02-05

10.  Exploring molecular mechanisms of ligand recognition by opioid receptors with metadynamics.

Authors:  Davide Provasi; Andrea Bortolato; Marta Filizola
Journal:  Biochemistry       Date:  2009-10-27       Impact factor: 3.162

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.